HAYA Therapeutics
Lausanne
About HAYA Therapeutics
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potential treatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $1.1B
- Funding stage: Early Stage Venture
- Last round: Grant (Sep 2025)
- Website: hayatx.com
Industries & Categories
Biotechnology, Genetics, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/haya-therapeutics-33671 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.